For Use Under the Emergency Use Authorization (EUA) Only

For In Vitro Diagnostic Use

Rx Only

FOR USE ON ACCESS FAMILY OF IMMUNOASSAY SYSTEMS

Samples should be collected from individuals within 8 days to 30 days post symptom onset. Samples should not be tested less than 8 days post symptom onset. Negative samples collected for 8 days post symptom onset should be reflexed to direct detection of the virus. Negative samples collected 8 days or more post symptom onset should be reflexed to a test that detects and reports SARS-CoV-2 IgG.

ANNUAL REVIEW

<table>
<thead>
<tr>
<th>Reviewed by</th>
<th>Date</th>
<th>Reviewed by</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PRINCIPLE

CAUTION

For U.S.A. only, Federal law restricts this device to sale and distribution by or on the order of a physician, or to a clinical laboratory; and use is restricted to by or on the order of a physician.

INTENDED USE

The Access SARS-CoV-2 IgM is a paramagnetic particle, chemiluminescent immunoassay intended for the qualitative detection of IgM antibodies to SARS-CoV-2 in human serum, serum separator tubes and plasma (lithium heparin, dipotassium EDTA, tripotassium EDTA, sodium citrate). The Access SARS-CoV-2 IgM is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. The Access SARS-CoV-2 IgM should not be used to diagnose acute SARS-CoV-2 infection. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform moderate or high complexity tests.
Results are for the detection of SARS-CoV-2 antibodies. IgM antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. Individuals may have detectable virus present for several weeks following seroconversion.

Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities.

The sensitivity of the Access SARS-CoV-2 IgM assay early after infection is unknown. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, direct testing for SARS-CoV-2 is necessary.

False positive results for the Access SARS-CoV-2 IgM assay may occur due to cross-reactivity from pre-existing antibodies or other possible causes. Due to the risk of false positive results, confirmation of positive results should be considered using a second different assay.

Samples should only be tested from individuals with that are 8 days to 30 days post symptom onset. SARS-CoV-2 antibody negative samples collected 8 days or more post symptom onset should be reflexed to a test that detects and reports SARS-CoV-2 IgG.

The Access SARS-CoV-2 IgM assay is only for use under the Food and Drug Administration's Emergency Use Authorization.

SUMMARY AND EXPLANATION

Coronavirus disease-2019 (COVID-19) is caused by a novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which has spread worldwide in 2020 causing a global pandemic. COVID-19 is characterized by fatigue, fever, cough, shortness of breath and other respiratory symptoms. The virus uses the transmembrane receptor angiotensin-converting enzyme 2 (ACE-2) to infect epithelial cells in the airways and lungs. Some individuals infected with SARS-CoV-2 have no, or mild symptoms while others develop severe respiratory distress requiring mechanical ventilation. Infected individuals develop an immune response to the virus in the form of anti-SARS-CoV-2 IgM and IgG antibodies over the course of days to weeks. Testing for the presence of IgM/IgG antibodies to SARS-CoV-2 can help to inform clinical management of patients with recent or prior COVID-19.

Serology testing is essential for COVID-19 surveillance. Testing for antibodies to the SARS-CoV-2 virus assists with an understanding of how the disease has spread in a particular population.

METHODOLOGY

The Access SARS-CoV-2 IgM assay is a two-step immunocapture immunoassay. A prediluted patient sample is added to a reaction vessel along with paramagnetic particles coated with a mouse monoclonal anti-human IgM antibody. Human IgM present in the patient specimen is captured by the anti-human IgM antibody on the paramagnetic particles. After incubation, materials bound to the solid phase are held in a magnetic field while unbound materials are washed away. Conjugate diluent and recombinant SARS-CoV-2 protein alkaline phosphatase conjugate are added to the vessel. The recombinant SARS-CoV-2 protein contains the receptor binding domain (RBD) of the viral S1 protein. The conjugate will bind to any anti-SARS-CoV-2 IgM that was captured by the paramagnetic particle solid phase in the first step. Following a second incubation and wash step, a chemiluminescent substrate is added to the vessel and light generated by the reaction of substrate and alkaline phosphatase is measured with a luminometer. By comparison of the light intensity with the cut-off value determined during calibration on the instrument, the presence or absence of anti-SARS-CoV-2 IgM is determined.

SPECIMEN

SPECIMEN STORAGE AND STABILITY
### Stability

<table>
<thead>
<tr>
<th>Specimen</th>
<th>Type</th>
<th>20°C to 25°C (hours)</th>
<th>2°C to 8°C (hours)</th>
<th>-20°C or colder (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum</td>
<td>Serum separator tube</td>
<td>8</td>
<td>48</td>
<td>30</td>
</tr>
<tr>
<td>Plasma</td>
<td>Heparin EDTA Citrate</td>
<td>8</td>
<td>48</td>
<td>30</td>
</tr>
</tbody>
</table>

Thaw samples only once.

### SPECIMEN COLLECTION AND PREPARATION

#### Blood Specimen

1. The role of preanalytical factors in laboratory testing has been described in a variety of published literature. To minimize the effect of preanalytical factors observe the following recommendations for handling and processing blood samples:

   A. Collect all blood samples observing routine precautions for venipuncture.
      a. Follow blood collection tube manufacturer’s recommendations for centrifugation.
      b. Ensure residual fibrin and cellular matter has been removed prior to analysis.

   B. Allow serum samples to clot completely before centrifugation in a vertical position, with the collection tube closure directed upwards.
      a. Follow the tube manufacturer’s recommendations for the length of serum/cell contact time before centrifuging samples. The clotting may be slower at cooler temperatures, or if the patient is on anticoagulant therapy.

2. Each laboratory should determine the acceptability of its own blood collection tubes and separation products that are in use. There may be variations in these products between manufacturers and between manufacturing lots.

3. Alternate collection types may be appropriate if the laboratory has established its own performance characteristics as defined by applicable law.

4. Avoid assaying lipemic or hemolyzed samples.

### REAGENTS

#### CONTENTS

**Access SARS-CoV-2 IgM Reagent Pack**

Ref. No. C58957, 200 determinations, 2 packs, 100 tests/pack

<table>
<thead>
<tr>
<th>Well</th>
<th>Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>R1a:</td>
<td>Paramagnetic particles coated with mouse anti-human IgM antibody in TRIS buffer with surfactant, protein (bovine), &lt; 0.1% sodium azide and 0.1% ProClin* 300.</td>
</tr>
<tr>
<td>R1b:</td>
<td>MES buffer, surfactant, protein (bovine), &lt; 0.1% sodium azide and 0.1% ProClin 300.</td>
</tr>
<tr>
<td>R1c:</td>
<td>MES buffer with recombinant SARS-CoV-2 protein alkaline phosphatase conjugate, surfactant, protein (bovine) &lt; 0.1% sodium azide and 0.1% ProClin 300.</td>
</tr>
</tbody>
</table>

*ProClin™ is a trademark of The Dow Chemical Company (“Dow”) or an affiliated company of Dow.
WARNING AND PRECAUTIONS

- For Emergency Use Authorization (EUA) only
- **For in vitro diagnostic use.**
- This test has not been FDA cleared or approved; this test has been authorized by FDA under an EUA for use by laboratories certified under CLIA, that meet requirements to perform moderate or high complexity tests.
- This test has been authorized only for the presence of IgM antibodies against SARS-CoV-2, not for any other viruses or pathogens.
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
- Samples and blood-derived products may be routinely processed with minimum risk using the procedure described. However, handle these products as potentially infectious according to universal precautions and good clinical laboratory practices,\(^8\) regardless of their origin, treatment, or prior certification. Use an appropriate disinfectant for decontamination. Store and dispose of these materials and their containers in accordance with local regulations and guidelines.
- For hazards presented by the product refer to the following sections: REACTIVE INGREDIENTS and GHS HAZARD CLASSIFICATION.

REACTIVE INGREDIENTS

| Sodium azide preservative may form explosive compounds in metal drain lines. See NIOSH Bulletin: Explosive Azide Hazard (8/16/76). To avoid the possible build-up of azide compounds, flush wastepipes with water after the disposal of undiluted reagent. Sodium azide disposal must be in accordance with appropriate local regulations. |

GHS HAZARD CLASSIFICATION

<table>
<thead>
<tr>
<th>SARS-CoV-2 IgM Particles (Compartment R1a)</th>
<th>WARNING</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CAUTION</td>
</tr>
<tr>
<td></td>
<td>Sodium azide preservative may form explosive compounds in metal drain lines. See NIOSH Bulletin: Explosive Azide Hazard (8/16/76). To avoid the possible build-up of azide compounds, flush wastepipes with water after the disposal of undiluted reagent. Sodium azide disposal must be in accordance with appropriate local regulations.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SARS-CoV-2 IgM Particles (Compartment R1a)</th>
<th>WARNING</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CAUTION</td>
</tr>
<tr>
<td></td>
<td>Sodium azide preservative may form explosive compounds in metal drain lines. See NIOSH Bulletin: Explosive Azide Hazard (8/16/76). To avoid the possible build-up of azide compounds, flush wastepipes with water after the disposal of undiluted reagent. Sodium azide disposal must be in accordance with appropriate local regulations.</td>
</tr>
</tbody>
</table>

H317 May cause an allergic skin reaction.
H412 Harmful to aquatic life with long lasting effects.
P273 Avoid release to the environment.
P280 Wear protective gloves, protective clothing and eye/face protection.
P333+P313 If skin irritation or rash occurs: Get medical advice/attention.
P362+P364 Take off contaminated clothing and wash it before use.

reaction mass of: 5-chloro-2-methyl-4-isothiazolin -3-one \([\text{EC# } 247-500-7]\) and 2-methyl-4-isothiazolin-3-one \([\text{EC# } 220-239-6]\)(3:1) < 0.05%
**WARNING**

H317 May cause an allergic skin reaction.

H412 Harmful to aquatic life with long lasting effects.

P273 Avoid release to the environment.

P280 Wear protective gloves, protective clothing and eye/face protection.

P333+P313 If skin irritation or rash occurs: Get medical advice/attention.

P362+P364 Take off contaminated clothing and wash it before use.

**SARS-CoV-2 IgM Conjugate (Compartment R1c)**

reaction mass of: 5-chloro-2-methyl-4-isothiazolin -3-one [EC# 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1) < 0.05%

---

**MATERIALS NEEDED BUT NOT SUPPLIED WITH REAGENT KIT**

1. Access SARS-CoV-2 IgM Calibrator
   Provided as one negative and one positive for SARS-CoV-2 IgM
   Ref. No. C58958

2. QC (Quality Control) materials: Access SARS-CoV-2 IgM QC
   Ref. No. C58959

3. Access Substrate

---

Safety Data Sheet is available at beckmancoulter.com/techdocs
   UniCel DxI Wash Buffer II, Ref. No. A16793

REAGENT PREPARATION

Provided ready to use.

REAGENT STORAGE AND STABILITY

<table>
<thead>
<tr>
<th>Stability</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Unopened at 2°C to 10°C</td>
<td>Up to stated Expiration Date</td>
</tr>
<tr>
<td>After opening at 2°C to 10°C</td>
<td>28 days</td>
</tr>
</tbody>
</table>

- Store upright.
- Refrigerate at 2°C to 10°C for a minimum of two hours before use on the instrument.
- Signs of possible deterioration are a broken elastomeric layer on the pack or quality control values out of range.
- If the reagent pack is damaged (e.g., a broken elastomer), discard the pack.
- Discard reagents if any discoloration is observed.
- Do not use reagents after the expiration date indicated on the box label.

CALIBRATION

CALIBRATION INFORMATION

An active calibration point is required for all tests. For the Access SARS-CoV-2 IgM assay, a calibration is required every 28 days. See calibrator Instructions for Use (IFU) for additional calibration information. Refer to the appropriate system manuals and/or Help system for information on calibration method, configuring calibrators, calibrator test request entry, and reviewing calibration data.

QUALITY CONTROL

Please refer to Quality Control Instructions for Use.

Quality control materials simulate the characteristics of samples and are essential for monitoring the system performance of immunochemical assays. Include quality control materials in each 24-hour time period, or as required by individual laboratory procedures, because samples may be processed at any time in a “random access” format rather than a “batch” format.

 Include Access SARS-CoV-2 IgM QC or other commercially available quality control materials that cover at least two levels of analyte.

More frequent use of quality controls or the use of additional controls is left to the discretion of the operator, based upon good laboratory practices or laboratory accreditation requirements and applicable laws. Follow manufacturer’s instructions for reconstituting and storing controls. Each laboratory should establish mean values and acceptable ranges to assure proper performance. Quality control results that do not fall within acceptable ranges may indicate invalid test results. Examine all test results that were generated since obtaining the last acceptable quality control test point for this analyte. Refer to the appropriate system manuals and/or Help system for information about reviewing quality control results.
TESTING PROCEDURE(S)

PROCEDURE
1. Refer to the appropriate system manuals and/or Help system for a specific description of installation, start-up, principles of operation, system performance characteristics, operating instructions, calibration procedures, operational limitations and precautions, hazards, maintenance, and troubleshooting.
   A. The system default unit of measure for sample results is S/CO.
2. Mix the contents of a new (unpunctured) reagent pack by gently inverting the pack several times before loading it on the instrument. Do not invert an open (punctured) pack.
3. Use ten (10) µL of sample for each determination, in addition to the sample container and system dead volumes, when requesting the SARS-CoV-2 IgM assay.
4. Refer to the appropriate system manuals and/or Help system for information on managing samples, configuring tests, requesting tests, and reviewing test results.

LIMITATIONS
1. Do not dilute samples as this could lead to incorrect results.
2. For assays that employ antibodies, the possibility exists for interference by heterophile antibodies in the test sample. Patients who are regularly exposed to animals, or are subjected to medical treatments that utilize immunoglobulins or immunoglobulin fragments, may produce human anti-animal antibodies, e.g. HAMA, that interfere with immunoassays. These interfering antibodies may cause erroneous results.
3. Other potential interferences could be present in the sample and may cause erroneous results in immunoassays. Some examples that are documented in literature include rheumatoid factor, endogenous alkaline phosphatase, fibrin, and proteins capable of binding to alkaline phosphatase. Carefully evaluate results if the sample is suspected of having these types of interferences.
4. The Access SARS-CoV-2 IgM assay results should be interpreted in light of the total clinical presentation of the patient, including: symptoms, clinical history, data from additional tests, and other appropriate information.
5. Results from antibody testing should not be used to diagnose or exclude acute SARS-CoV-2 infection or to inform infection status.
6. It is unknown at this time if the presence of antibodies to SARS-CoV-2 confers immunity to reinfection.
7. This assay is intended for qualitative detection only. Test value itself cannot be used to determine the quantity of SARS-CoV-2 IgM antibodies.
8. The magnitude of the measured result above the threshold is not indicative of the total amount of antibody present in the sample.
9. The individual immune response following SARS-CoV-2 infection varies considerably and might give different results with assays from different manufacturers. Results of assays from different manufacturers should not be used interchangeably.
10. Negative results do not preclude acute SARS-CoV-2 infection. IgM antibodies may not be detected in the first few days of infection; the sensitivity of the Access SARS-CoV-2 IgM assay early after infection is unknown. If acute infection is suspected, direct testing for SARS-CoV-2 is necessary.
11. SARS-CoV-2 IgM antibodies may be below detectable levels in patients who have been exhibiting symptoms for less than 8 days.
12. A negative result can occur if the quantity of antibodies for the SARS-CoV-2 virus present in the specimen is below the detection limit of the assay, or if the virus has undergone minor amino acid mutation(s) in the epitope recognized by the antibody used in the test.
13. A positive result may not indicate previous SARS-CoV-2 infection. Consider other information, including clinical history and local disease prevalence, in assessing the need for an alternative serology test to confirm an immune
response. Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.

14. False positive test results for IgM antibodies can occur due to cross-reactivity with pre-existing antibodies or from other possible causes.

15. This test is not to be used for screening donated blood.

Conditions of Authorization for the Laboratory


1. Authorized laboratories* using your product will include with test result reports, all authorized Fact Sheets. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.

2. Authorized laboratories using your product will use your product as outlined in the authorized labeling. Deviations from the authorized procedures, including the authorized instruments, authorized clinical specimen types, authorized control materials, authorized other ancillary reagents and authorized materials required to use your product are not permitted.

3. Authorized laboratories that receive your product will notify the relevant public health authorities of their intent to run your product prior to initiating testing.

4. Authorized laboratories using your product will have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate.

5. Authorized laboratories will collect information on the performance of your product and report to DMD/OHT7-OIR/OPEQ/CDRH (via email: CDRH-EUA-Reporting@fda.hhs.gov) and Beckman Coulter, Inc. (www.beckmancoulter.com) any suspected occurrence of false reactive or false non-reactive results and significant deviations from the established performance characteristics of your product of which they become aware.

6. All laboratory personnel using your product must be appropriately trained in automated immunoassay techniques and use appropriate laboratory and personal protective equipment when handling this kit, and use your product in accordance with the authorized labeling. All laboratory personnel using the assay must also be trained in and be familiar with the interpretation of results of the product.

7. Beckman Coulter, Inc., authorized distributors, and authorized laboratories using your product will ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.

*R The letter of authorization refers to, “Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform moderate or high complexity tests” as "authorized laboratories."

RESULTS INTERPRETATION

Test results are determined automatically by the system software. Detection of analyte in the sample is determined from the measured light production by means of the stored calibration data. Results are reported as reactive or non-reactive. Refer to the appropriate system manuals and/or Help system for complete instructions for a qualitative assay and reviewing sample results.
Result Interpretation Reporting Instructions

<table>
<thead>
<tr>
<th>Result</th>
<th>Interpretation</th>
<th>Reporting Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 1.00 S/CO SARS-CoV-2 IgM</td>
<td>Non-Reactive</td>
<td>Report result as non-reactive for SARS-CoV-2 IgM antibodies</td>
</tr>
<tr>
<td>≥ 1.00 S/CO SARS-CoV-2 IgM</td>
<td>Reactive</td>
<td>Report result as reactive for SARS-CoV-2 IgM antibodies</td>
</tr>
</tbody>
</table>

**PERFORMANCE CHARACTERISTICS**

**POSITIVE AGREEMENT**

The positive percent agreement (PPA) of the Access SARS-CoV-2 IgM assay was evaluated in 173 individual serum and plasma samples from symptomatic subjects diagnosed with SARS-CoV-2 by PCR methods from France and the United States. The results are presented in the following table, classified by days between symptom onset and the blood sample draw. The 95% confidence interval was determined by the Wilson Score method.

<table>
<thead>
<tr>
<th>Days post symptom onset</th>
<th>Total Samples</th>
<th>Number Non-Reactive</th>
<th>Number Reactive</th>
<th>PPA   (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 - 7</td>
<td>22</td>
<td>10</td>
<td>12</td>
<td>54.5% (34.7 - 73.1%)</td>
</tr>
<tr>
<td>8 - 14</td>
<td>36</td>
<td>3</td>
<td>33</td>
<td>91.7% (78.2 - 97.1%)</td>
</tr>
<tr>
<td>15 - 30</td>
<td>115</td>
<td>2</td>
<td>113</td>
<td>98.3% (93.9 - 99.5%)</td>
</tr>
</tbody>
</table>

The positive percent agreement of the Access SARS-CoV-2 IgM assay for all serum and plasma samples tested was 91.3% (158/173; 95% CI 86.2 - 94.7%).

**NEGATIVE AGREEMENT**

The negative percent agreement (NPA) of the Access SARS-CoV-2 IgM assay was evaluated in a study of 1,400 samples collected prior to December 2019* in France and the United States. This total includes 1,000 samples from blood donors in France and 200 samples each from routine clinical laboratory diagnostic samples in France and the United States. Based on this evaluation, the overall negative percent agreement of the Access SARS-CoV-2 IgM assay is 99.9% (1,398/1,400), with a 95% confidence interval of 99.5 - 100.0% determined by the Wilson Score method.

<table>
<thead>
<tr>
<th>Population</th>
<th>Total Samples</th>
<th>Number Non-Reactive</th>
<th>Number Reactive</th>
<th>NPA   (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood Donors (France)</td>
<td>1,000</td>
<td>999</td>
<td>1</td>
<td>99.9% (99.4 - 100.0%)</td>
</tr>
<tr>
<td>Diagnostic Samples</td>
<td>200</td>
<td>199</td>
<td>1</td>
<td>99.5% (97.2 - 99.9%)</td>
</tr>
<tr>
<td>(France)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diagnostic Samples</td>
<td>200</td>
<td>200</td>
<td>0</td>
<td>100.0% (98.1 - 100.0%)</td>
</tr>
<tr>
<td>(United States)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>1,400</td>
<td>1,398</td>
<td>2</td>
<td>99.9% (99.5 - 100.0%)</td>
</tr>
</tbody>
</table>

*It has been shown that over 90% of the adult population have antibodies to all four common circulating coronaviruses.10,11
LONGITUDINAL STUDY

The serological status was evaluated in a panel of 51 serum and plasma specimens collected from 14 individuals from the date of symptom onset. Of the 14 individual patients, 12 showed positive results in all blood draws for the Access SARS-CoV-2 IgM, and 2 patients showed a change in SARS-CoV-2 IgM status. The results for 3 patients are listed in the following table along with corresponding results from the Access SARS-CoV-2 IgG test.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Draw</th>
<th>Days post symptom onset</th>
<th>IgM Result (S/CO)</th>
<th>IgM Interpretation</th>
<th>IgG Result (S/CO)</th>
<th>IgG Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>1</td>
<td>4</td>
<td>1.73</td>
<td>Reactive</td>
<td>0.15</td>
<td>Non-reactive</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>8</td>
<td>17.33</td>
<td>Reactive</td>
<td>17.04</td>
<td>Reactive</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>10</td>
<td>17.89</td>
<td>Reactive</td>
<td>40.76</td>
<td>Reactive</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>12</td>
<td>17.09</td>
<td>Reactive</td>
<td>50.54</td>
<td>Reactive</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>14</td>
<td>17.74</td>
<td>Reactive</td>
<td>55.93</td>
<td>Reactive</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>17</td>
<td>18.17</td>
<td>Reactive</td>
<td>52.59</td>
<td>Reactive</td>
</tr>
<tr>
<td>B</td>
<td>1</td>
<td>20</td>
<td>0.36</td>
<td>Non-reactive</td>
<td>0.32</td>
<td>Non-reactive</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>23</td>
<td>13.05</td>
<td>Reactive</td>
<td>53.38</td>
<td>Reactive</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>26</td>
<td>13.53</td>
<td>Reactive</td>
<td>60.84</td>
<td>Reactive</td>
</tr>
<tr>
<td>C</td>
<td>1</td>
<td>13</td>
<td>3.67</td>
<td>Reactive</td>
<td>49.36</td>
<td>Reactive</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>19</td>
<td>3.06</td>
<td>Reactive</td>
<td>42.86</td>
<td>Reactive</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>22</td>
<td>1.88</td>
<td>Reactive</td>
<td>38.43</td>
<td>Reactive</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>27</td>
<td>1.62</td>
<td>Reactive</td>
<td>34.77</td>
<td>Reactive</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>33</td>
<td>0.83</td>
<td>Non-reactive</td>
<td>25.31</td>
<td>Reactive</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>40</td>
<td>0.73</td>
<td>Non-reactive</td>
<td>19.83</td>
<td>Reactive</td>
</tr>
</tbody>
</table>

INTERFERING SUBSTANCES

High concentrations of endogenous serum components were assessed for interference in the Access SARS-CoV-2 IgM assay. The test protocol was based on CLSI EP07, Interference Testing in Clinical Chemistry, 3rd Edition. Human serum was spiked with a patient sample containing SARS-CoV-2 IgM antibodies to achieve a positive reactivity in the Access SARS-CoV-2 IgM assay. None of the substances tested demonstrated significant interference in the Access SARS-CoV-2 IgM assay as defined by a shift in concentration greater than 20% using the test concentrations indicated in the table below.

<table>
<thead>
<tr>
<th>Substance</th>
<th>Interferent Concentration Tested</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bilirubin (conjugated)</td>
<td>43 mg/dL</td>
</tr>
<tr>
<td>Bilirubin (unconjugated)</td>
<td>43 mg/dL</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>300 mg/dL</td>
</tr>
<tr>
<td>Triglycerides (intralipid)</td>
<td>1,771 mg/dL</td>
</tr>
</tbody>
</table>
**CROSS REACTIVITY**

Cross-reactivity of the Access SARS-CoV-2 IgM assay was evaluated by testing serum and plasma samples for each of the potentially cross-reacting conditions listed in the following table. The following table shows the cross-reactivity results.

<table>
<thead>
<tr>
<th>Category</th>
<th>Number of Samples</th>
<th>Number of Reactive Samples</th>
<th>Number of Non-Reactive Samples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Influenza A</td>
<td>5</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Anti-Influenza B</td>
<td>5</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Anti-Hepatitis C Virus (HCV)</td>
<td>16</td>
<td>1</td>
<td>15</td>
</tr>
<tr>
<td>Anti-Hepatitis B Virus (HBV)</td>
<td>17</td>
<td>0</td>
<td>17</td>
</tr>
<tr>
<td>Anti-HIV</td>
<td>10</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>Anti-Nuclear Antibodies (ANA)</td>
<td>10</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>Anti-Adenovirus Positive IgG</td>
<td>2</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Cytomegalovirus (CMV) IgM</td>
<td>9</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td>Rheumatoid Factor (RF) Total</td>
<td>14</td>
<td>0</td>
<td>14</td>
</tr>
<tr>
<td>Rheumatoid Factor (RF) IgM</td>
<td>15</td>
<td>1</td>
<td>14</td>
</tr>
</tbody>
</table>

**ADDITIONAL INFORMATION**

Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other Countries.

May be covered by one or more pat. -see www.beckmancoulter.com/patents.

**REVISION HISTORY**

**Revision A**

New release.

**Revision B**

Reagent and Quality Control use update.

**Revision C**

Intended Use update.

**SYMBOLS KEY**

Glossary of Symbols is available at beckmancoulter.com/techdocs (document number C02724).
REFERENCES


EC REP Beckman Coulter Eurocenter S.A., 22, rue Juste-Olivier. Case Postale 1044, CH - 1260 Nyon 1, Switzerland
Tel: +41 (0)22 365 36 11

Beckman Coulter, Inc., 250 S. Kraemer Blvd., Brea, CA 92821 U.S.A.
www.beckmancoulter.com
For Use Under the Emergency Use Authorization (EUA) Only

For In Vitro Diagnostic Use

Rx Only

FOR USE ON ACCESS FAMILY OF IMMUNOASSAY SYSTEMS

ANNUAL REVIEW

<table>
<thead>
<tr>
<th>Reviewed by</th>
<th>Date</th>
<th>Reviewed by</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PRINCIPLE

CAUTION

For U.S.A. only, Federal law restricts this device to sale and distribution by or on the order of a physician, or to a clinical laboratory; and use is restricted to by or on the order of a physician.

INTENDED USE

The Access SARS-CoV-2 IgM Calibrators are intended to calibrate the Access SARS-CoV-2 IgM assay for the in vitro qualitative detection of SARS-CoV-2 IgM antibodies in human serum, serum separator tubes and plasma (lithium heparin, dipotassium EDTA, tripotassium EDTA, sodium citrate) for use on the Access Family of Immunoassay Systems only.

SUMMARY AND EXPLANATION

The Access SARS-CoV-2 IgM Calibrator is used to establish calibration (determine the cut-off value) for the Access SARS-CoV-2 IgM assay. By comparing the light intensity generated by a sample to the cut-off value, the presence or absence of SARS-CoV-2 IgM antibodies in the sample is determined.

TRACEABILITY

The analyte in the Access SARS-CoV-2 IgM Calibrator is traceable to the manufacturer’s working calibrators. Traceability process is based on EN ISO 17511.
The assigned values were established using representative samples from this lot of calibrator, and are specific to the assay methodologies of the Access reagents. The values assigned by other methodologies may be different. Such differences, if present, may be caused by inter-method bias.

**REAGENTS**

**CONTENTS**

**Access SARS-CoV-2 IgM Calibrator**
**Ref. No. C58958: C0-C1, 2.0 mL/vial**

- Provided ready to use.
- Store upright and refrigerate at 2 to 10°C.
- Mix contents by gently inverting before use. Avoid bubble formation.
- Stable until the expiration date stated on the label when stored at 2 to 10°C.
- Vial is stable at 2 to 10°C for 90 days after initial use.
- Signs of possible deterioration are quality control values out of range.
- Refer to calibration card for exact concentrations.

<table>
<thead>
<tr>
<th>C0:</th>
<th>TRIS buffer, surfactant and protein (bovine), &lt; 0.1% sodium azide and 0.5% ProClin* 300.</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1:</td>
<td>TRIS buffer containing anti-SARS-CoV-2 IgM positive plasma, surfactant, and protein (bovine), &lt; 0.1% sodium azide and 0.5% ProClin 300.</td>
</tr>
<tr>
<td>Calibration Card:</td>
<td>1</td>
</tr>
</tbody>
</table>

*ProClin™ is a trademark of The Dow Chemical Company (“Dow”) or an affiliated company of Dow.

**WARNING AND PRECAUTIONS**

- For Emergency Use Authorization (EUA) only
- For *in vitro* diagnostic use.
- Samples and blood-derived products may be routinely processed with minimum risk using the procedure described. However, handle these products as potentially infectious according to universal precautions and good clinical laboratory practices,¹ regardless of their origin, treatment, or prior certification. Use an appropriate disinfectant for decontamination. Store and dispose of these materials and their containers in accordance with local regulations and guidelines.
- The antibody used to prepare the reagent is derived from human plasma. Always consider these products to be potentially infectious. Regardless of their origin, treatment, or prior certification, handle them according to universal precautions and good clinical laboratory practices. Use an appropriate disinfectant for decontamination. Store and dispose of these materials and their containers according to local regulations and guidelines.²
- For hazards presented by the product refer to the following sections: REACTIVE INGREDIENTS and GHS HAZARD CLASSIFICATION.
- This product has not been FDA cleared or approved; this product has been authorized by FDA under an EUA for Use by laboratories certified under CLIA, that meet requirements to perform moderate or high complexity tests.
- This product has been authorized only for the presence of IgM antibodies against SARS-CoV-2, not for any other viruses or pathogens;
- This product is only authorized for the duration of the declaration that circumstances exist justifying the Authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

---

[1] Universal precautions: Basic infection control procedures that apply to all healthcare workers who perform procedures on patients and to all healthcare settings. These procedures are designed to reduce the risk of infection to patients and healthcare workers. Universal precautions include the use of gloves and other protective equipment, the use of disinfectants and other cleaning agents to decontaminate surfaces, and the proper disposal of contaminated waste.

[2] Good clinical laboratory practices (GCLPs): These are practices designed to ensure the safety and accuracy of laboratory tests. GCLPs include the use of appropriate personal protective equipment, the proper handling of biological materials, and the careful documentation of all procedures performed.
REACTIVE INGREDIENTS

![CAUTION]

Sodium azide preservative may form explosive compounds in metal drain lines. See NIOSH Bulletin: Explosive Azide Hazard (8/16/76). To avoid the possible build-up of azide compounds, flush wastepipes with water after the disposal of undiluted reagent. Sodium azide disposal must be in accordance with appropriate local regulations.

GHS HAZARD CLASSIFICATION

SARS-CoV-2 IgM C0  WARNING

- H317 May cause an allergic skin reaction.
- H412 Harmful to aquatic life with long lasting effects.
- P273 Avoid release to the environment.
- P280 Wear protective gloves, protective clothing and eye/face protection.
- P333+P313 If skin irritation or rash occurs: Get medical advice/attention.
- P362+P364 Take off contaminated clothing and wash it before use.

reaction mass of: 5-chloro-2-methyl-4-isothiazolin -3-one [EC# 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1) < 0.05%

SARS-CoV-2 IgM C1  WARNING

- H317 May cause an allergic skin reaction.
- H412 Harmful to aquatic life with long lasting effects.
- P273 Avoid release to the environment.
- P280 Wear protective gloves, protective clothing and eye/face protection.
- P333+P313 If skin irritation or rash occurs: Get medical advice/attention.
- P362+P364 Take off contaminated clothing and wash it before use.

reaction mass of: 5-chloro-2-methyl-4-isothiazolin -3-one [EC# 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1) < 0.05%

Safety Data Sheet is available at beckmancoulter.com/techdocs
CALIBRATION

CALIBRATION INFORMATION

The Access SARS-CoV-2 IgM Calibrators are provided as: negative and positive. Assay calibration data are valid up to 28 days.

Run the calibrators in triplicate.

TESTING PROCEDURE(S)

PROCEDURE

Refer to the appropriate system manuals and/or Help system for information on calibration theory, configuring calibrators, calibrator test request entry, and reviewing calibration data.

PROCEDURAL NOTES

LIMITATIONS

If there is evidence of microbial contamination or excessive turbidity in a reagent, discard the vial.

ADDITIONAL INFORMATION

Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other Countries.

May be covered by one or more pat. -see www.beckmancoulter.com/patents.

REVISION HISTORY

Revision A
New release.

SYMBOLS KEY

Glossary of Symbols is available at beckmancoulter.com/techdocs (document number C02724).
REFERENCES


For Use Under the Emergency Use Authorization (EUA) Only

For In Vitro Diagnostic Use

Rx Only

FOR USE ON ACCESS FAMILY OF IMMUNOASSAY SYSTEMS

ANNUAL REVIEW

<table>
<thead>
<tr>
<th>Reviewed by</th>
<th>Date</th>
<th>Reviewed by</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PRINCIPLE

CAUTION

For U.S.A. only, Federal law restricts this device to sale and distribution by or on the order of a physician, or to a clinical laboratory; and use is restricted to by or on the order of a physician.

INTENDED USE

The Access SARS-CoV-2 IgM QC is intended for monitoring system performance of the Access SARS-CoV-2 IgM assay.

The Access SARS-CoV-2 IgM QC is for use on the Access Family of Immunoassay Systems only.

SUMMARY AND EXPLANATION

Quality control (QC) materials simulate the characteristics of patient samples and are essential for monitoring the system performance of the Access SARS-CoV-2 IgM immunoassay. In addition, they are an integral part of good laboratory practices. When performing assays with Access reagents for SARS-CoV-2 IgM, include quality control materials to validate the integrity of the assays. The assayed values should fall within the acceptable range if the test system is working properly.

TRACEABILITY

The analyte in the Access SARS-CoV-2 IgM QC is traceable to the manufacturer’s working calibrators. Traceability process is based on EN ISO 17511. The assigned values were established using representative samples from this lot of
QC, and are specific to the assay methodologies of the Access reagents. The values assigned by other methodologies may be different. Such differences, if present, may be caused by inter-method bias.

**REAGENTS**

**CONTENTS**

**Access SARS-CoV-2 IgM QC**  
Ref. No. C58959: QC1-QC2, 4 mL/vial, 3 vials each level  
- Provided ready to use.  
- Store upright and refrigerate at 2 to 10°C.  
- Mix contents by gently inverting before use. Avoid bubble formation.  
- Stable until the expiration date stated on the label when stored at 2 to 10°C.  
- Vial is stable at 2 to 10°C for 30 days after initial use.  
- Signs of possible deterioration are quality control values out of range.  
- Refer to the QC value card for mean values and standard deviations (SD).

| QC1: Negative | TRIS buffer, defibrinated human plasma negative for anti-SARS-CoV-2, surfactant, protein (bovine), < 0.1% sodium azide and 0.5% ProClin* 300. |
| QC2: Positive | TRIS buffer, defibrinated human plasma, human IgM conjugated to anti-SARS-CoV-2 antibodies, surfactant, protein (bovine), < 0.1% sodium azide and 0.5% ProClin 300. |
| QC Value Card: | 1 |

*ProClin™ is a trademark of The Dow Chemical Company (“Dow”) or an affiliated company of Dow.

**WARNING AND PRECAUTIONS**

- For Emergency Use Authorization (EUA) only
- **For in vitro diagnostic use.**
- Samples and blood-derived products may be routinely processed with minimum risk using the procedure described. However, handle these products as potentially infectious according to universal precautions and good clinical laboratory practices, regardless of their origin, treatment, or prior certification. Use an appropriate disinfectant for decontamination. Store and dispose of these materials and their containers in accordance with local regulations and guidelines.
- The antibody used to prepare the reagent is derived from human plasma. Always consider these products to be potentially infectious. Regardless of their origin, treatment, or prior certification, handle them according to universal precautions and good clinical laboratory practices. Use an appropriate disinfectant for decontamination. Store and dispose of these materials and their containers according to local regulations and guidelines.
- For hazards presented by the product refer to the following sections: REACTIVE INGREDIENTS and GHS HAZARD CLASSIFICATION.
- This product has not been FDA cleared or approved; this product has been authorized by FDA under an EUA for use by laboratories certified under CLIA, that meet requirements to perform moderate or high complexity tests.
- This product has been authorized only for the presence of IgM antibodies against SARS-CoV-2, not for any other viruses or pathogens.
- This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
CAUTION

Sodium azide preservative may form explosive compounds in metal drain lines. See NIOSH Bulletin: Explosive Azide Hazard (8/16/76). To avoid the possible build-up of azide compounds, flush wastepipes with water after the disposal of undiluted reagent. Sodium azide disposal must be in accordance with appropriate local regulations.

GHS HAZARD CLASSIFICATION

SARS-CoV-2 IgM QC1 WARNING

H317 May cause an allergic skin reaction.
H412 Harmful to aquatic life with long lasting effects.
P273 Avoid release to the environment.
P280 Wear protective gloves, protective clothing and eye/face protection.
P333+P313 If skin irritation or rash occurs: Get medical advice/attention.
P362+P364 Take off contaminated clothing and wash it before use.

reaction mass of: 5-chloro-2-methyl-4-isothiazolin -3-one [EC# 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1) < 0.05%

SARS-CoV-2 IgM QC2 WARNING

H317 May cause an allergic skin reaction.
H412 Harmful to aquatic life with long lasting effects.
P273 Avoid release to the environment.
P280 Wear protective gloves, protective clothing and eye/face protection.
P333+P313 If skin irritation or rash occurs: Get medical advice/attention.
P362+P364 Take off contaminated clothing and wash it before use.

reaction mass of: 5-chloro-2-methyl-4-isothiazolin -3-one [EC# 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1) < 0.05%

Safety Data Sheet is available at beckmancoulter.com/techdocs
TESTING PROCEDURE(S)

PROCEDURE

Use the Access Immunoassay System to determine the concentration of SARS-CoV-2 IgM in the Access SARS-CoV-2 IgM QC materials in the same manner as a sample. Include quality control materials in each 24-hour time period, or as required by individual laboratory procedures, because samples may be processed at any time in a “random access” format rather than a “batch” format. More frequent use of controls or the use of additional controls is left to the discretion of the operator, based upon good laboratory practices or the laboratory accreditation requirements and applicable laws. Refer to the appropriate system manuals and/or Help system for information on quality control theory, configuring controls, quality control sample test request entry, and reviewing quality control data.

REPORTING RESULTS

EXPECTED RESULTS

For the value assignment of Access SARS-CoV-2 IgM QC material, select and assay a number of samples that are representative of the entire lot to provide a reliable estimate of the mean value. The mean values and standard deviations are listed on the QC value card. There are variations, such as technique, equipment, or reagents, which may cause results that are different from the listed values. Therefore, each laboratory should establish its own mean values and standard deviations (SD). Patient results should not be reported if QC values are outside of expected ranges.

PROCEDURAL NOTES

LIMITATIONS

If there is evidence of microbial contamination or excessive turbidity in a reagent, discard the vial.

ADDITIONAL INFORMATION

Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other Countries.

May be covered by one or more patent - see www.beckmancoulter.com/patents.

REVISION HISTORY

Revision A
New release.

Revision B
Expected results update.

SYMBOLS KEY

Glossary of Symbols is available at beckmancoulter.com/techdocs (document number C02724).
REFERENCES


Beckman Coulter Eurocenter S.A., 22, rue Juste-Olivier. Case Postale 1044, CH - 1260 Nyon 1, Switzerland
Tel: +41 (0)22 365 36 11

Beckman Coulter, Inc., 250 S. Kraemer Blvd., Brea, CA 92821 U.S.A.
www.beckmancoulter.com